Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 21;28(1):107-114.
doi: 10.3390/curroncol28010014.

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

Domen Ribnikar  1 , Igor Stukalin  2 , Philippe L Bedard  1 , Robert J Hamilton  3 , Michael Jewett  3 , Padraig Warde  4 , Peter Chung  4 , Lynn Anson-Cartwright  4 , Arnoud J Templeton  5 , Eitan Amir  1 , Aaron R Hansen  1 , Daniel Y C Heng  2 , Jeremy Lewin  1
Affiliations

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

Domen Ribnikar et al. Curr Oncol. .

Abstract

We investigated the prognostic utility of pre-chemotherapy neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic germ cell tumors (GCTs) undergoing first-line chemotherapy. We utilized two institutional databases to analyze the pretreatment-derived NLR (dNLR). Predictive accuracy was evaluated using the Cox proportional hazard model adjusted for the international germ cell cancer collaborative group (IGCCCG) risk classification. Discriminatory accuracy was evaluated by determining the area under the receiver operating characteristic curve (AUROC). In total, 569 of 690 patients had available dNLR (IGCCCG: good, 64%; intermediate, 21%; poor, 16%). The 5-year and 10-year overall survivals (OSs) for good, intermediate, and poor risk groups were 96.2%, 92.8%, and 62.7% and 93.9%, 90.3%, and 62.7%, respectively. A dNLR of 2 provided the best discriminatory accuracy with an AUROC of 0.58 (95% CI: 0.52-0.65, p = 0.01) for progression-free survival (PFS), whereas for OS, a dNLR of 3 provided the best discriminatory accuracy with an AUROC of 0.62 (95% CI: 0.53-0.70, p < 0.01). A dNLR > 2 was associated with a hazard ratio (HR) of 1.99 (95% CI: 1.27-3.12, p < 0.01) for PFS, which lost its effect after adjustment for IGCCCG (HR: 1.44, 95% CI: 0.90-2.30, p = 0.13). For OS, a dNLR >3 was associated with an HR of 3.00 (95% CI: 1.79-5.01, p < 0.01), but lost its effect after adjustment for IGCCCG. Systemic inflammation plays a role in metastatic GCT, but its prognostic utility beyond established algorithms is limited. The general prognostic value of NLR can be seen across a number of tumors, although the consistency and magnitude of the effect differ according to cancer type, disease stage, and treatment received. We identified that an elevated NLR was associated with an adverse PFS and OS, but not independent of the IGCCCG risk classification. dNLRs >2 and >3 were associated with an adverse PFS and OS, respectively, in patients with metastatic GCT receiving first-line chemotherapy, but not independent of the IGCCCG risk classification.

Keywords: germ cell tumors; metastatic disease; neutrophil-to-lymphocyte ratio; prognosis; testicular cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curves of overall survival (OS) according to the IGCCCG group.
Figure 2
Figure 2
Discriminatory accuracy (AUROC) of the IGCCCG group and NLR, separate and combined for overall survival (OS).
See this image and copyright information in PMC

References

    1. Wilkinson P.M., Read G. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J. Clin. Oncol. 1997;15:594–603. doi: 10.1200/jco.1997.15.2.594. - DOI - PubMed
    1. Gillessen S., Collette L., Daugaard G., De Wit R., Tryakin A., Albany C., Stahl O., Fizazi K., Gietema J., De Giorgi U., et al. Redefining the IGCCCG classification in advanced non-seminoma. Ann. Oncol. 2019;30:v357–v358. doi: 10.1093/annonc/mdz249.002. - DOI
    1. Beyer J., Collette L., Daugaard G., De Wit R., Tryakin A., Albany C., Stahl O., Fizazi K., Gietema J.A., De Giorgi U., et al. Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium. J. Clin. Oncol. 2020;38:386. doi: 10.1200/JCO.2020.38.6_suppl.386. - DOI
    1. Van Dijk M.R., Steyerberg E.W., Habbema J.D.F. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur. J. Cancer. 2006;42:820–826. doi: 10.1016/j.ejca.2005.08.043. - DOI - PubMed
    1. Ko J.J., Bernard B., Tran B., Li H., Asif T., Stukalin I., Lee M., Day D., Alimohamed N., Sweeney C.J., et al. Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. J. Clin. Oncol. 2016;34:714–720. doi: 10.1200/JCO.2015.64.7909. - DOI - PubMed